European Medicines Agency Begins Review of Pfizer-Valneva Lyme Disease Vaccine Application

The European Medicines Agency has validated the Marketing Authorization Application for Pfizer and Valneva's 6-valent Lyme disease vaccine candidate, PF-07307405. This action initiates the EMA's formal assessment of the vaccine, which previously showed over 70% efficacy in a Phase 3 trial for individuals aged five and older. This is a critical step towards potential market approval and broader availability.